藥明生物(02269.HK)兩家子公司被美國商務部列入未經核實名單 明日復牌
格隆匯2月8日丨藥明生物(02269.HK)公吿,於2022年2月8日,公司注意到美國商務部工業與安全局已將其兩家子公司,即無錫藥明生物技術股份有限公司和上海藥明生物技術有限公司列入未經核實名單。公司瞭解將該等子公司列入未經核實名單是因為相關美國政府機構無法進行必要核實程序,以便自美國供應商處出口相應設備。未經核實名單與實體名單不同。列入未經核實名單並不意味着美國出口商不能與名單上的人士往來,也不意味着與有關人士存在具體、有價值、可闡述的國家安全或外交政策問題。
在過去十年中,公司嚴格遵循美國出口管制條例,一直獲得美國商務部批准進口部分受管制一次性生物反應器控制器和中空纖維過濾器。公司認為,本事件對公司為全球客户提供的服務不會產生重大不利影響,各項業務均正在穩步推進。同時監於上海及無錫相關設施建設完成後沒有進口相關儀器設備的需求,此事件對公司進口影響亦相對微小。儘管如此,公司正積極採取臨時措施,要求將該等子公司從未經核實名單移除。
此外,公司已向聯交所申請自2022年2月9日上午9時正起恢復公司股份的買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.